Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004)

European Urology
C R ChappleShane R Raines

Abstract

Improvements over existing treatment standards in overactive bladder (OAB) may only be possible through the development of drugs acting via non-cholinergic pathways. This is the first clinical study to be reported in full for the use of a potassium channel opener in OAB. This randomized, double-blind, placebo-controlled phase II study evaluated the efficacy and safety of ZD0947 (25mg/day for 12 weeks) in patients with OAB. The primary endpoint was mean volume voided per micturition per 24 hours. Key secondary endpoints were changes from baseline in mean numbers of micturition episodes (total, voluntary, and incontinent) per 24 hours. ZD0947 was not superior to placebo for the primary or secondary efficacy variables. The placebo-adjusted magnitude of effect for ZD0947 (approx. 4 mL) was less than the historic data for cholinergic antagonists (approx. 20 mL). Treatment was generally safe and well tolerated. The data for ZD0947 are disappointing. More studies are needed to advance the identification of novel, non-cholinergic therapies for OAB.

References

Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
Oct 30, 1999·International Urogynecology Journal and Pelvic Floor Dysfunction·H P DrutzS Radomski
Mar 15, 2001·Urology·P Van KerrebroeckUNKNOWN Tolterodine Study Group
May 6, 2004·The Journal of Urology·Norman ZinnerUNKNOWN Trospium Study Group
Oct 8, 2004·Expert Opinion on Therapeutic Targets·Murali Gopalakrishnan, Char-Chang Shieh
Oct 27, 2004·Expert Opinion on Investigational Drugs·Christopher R Chapple

❮ Previous
Next ❯

Citations

Jan 16, 2008·International Urogynecology Journal and Pelvic Floor Dysfunction·Emilio SaccoPierfrancesco Bassi
Dec 7, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Elfaridah P FrazierMartin C Michel
Jul 11, 2007·Postgraduate Medical Journal·Sushma SrikrishnaMaria Vella
Sep 1, 2012·Women's Health·Rosamund GrimshawPallavi Latthe
Jan 1, 2008·Expert Review of Clinical Pharmacology·Dudley Robinson, Linda Cardozo
Sep 12, 2015·Expert Opinion on Emerging Drugs·Roopali Karmarkar, Vik Khullar
Jun 28, 2007·Expert Opinion on Investigational Drugs·Enrico ColliLorenza Olivieri
Dec 27, 2011·Maturitas·Dudley Robinson, Linda Cardozo
Jan 26, 2010·Maturitas·Dudley Robinson, Linda Cardozo
Apr 9, 2011·Expert Opinion on Pharmacotherapy·Jerilyn M Latini, Antonella Giannantoni
Feb 9, 2011·Expert Opinion on Pharmacotherapy·Anastasios Athanasopoulos, Francisco Cruz
Aug 21, 2013·Maturitas·Dudley RobinsonLinda Cardozo
Feb 12, 2013·Maturitas·Dudley RobinsonLinda Cardozo
Nov 8, 2014·International Urogynecology Journal·Emilio Sacco, Riccardo Bientinesi
Jun 15, 2007·Current Opinion in Urology·Donna J Sellers, Neil McKay
Feb 10, 2020·International Journal of Urology : Official Journal of the Japanese Urological Association·Martin C Michel
May 19, 2009·Current Opinion in Urology·Karl-Erik AnderssonAlan J Wein
Jun 15, 2007·Current Opinion in Urology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.